Session » Abstracts: Sjögren’s Syndrome – Basic & Clinical Science
- 2:00PM-3:30PM
-
Abstract Number: 1638
CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden
- 2:00PM-3:30PM
-
Abstract Number: 1636
Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
- 2:00PM-3:30PM
-
Abstract Number: 1635
Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies
- 2:00PM-3:30PM
-
Abstract Number: 1633
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
- 2:00PM-3:30PM
-
Abstract Number: 1637
IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity